These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 25981639)

  • 1. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
    Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
    BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of novel L-threo-beta-benzyloxyaspartate derivatives, potent blockers of the glutamate transporters.
    Shimamoto K; Sakai R; Takaoka K; Yumoto N; Nakajima T; Amara SG; Shigeri Y
    Mol Pharmacol; 2004 Apr; 65(4):1008-15. PubMed ID: 15044631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3.
    Esslinger CS; Agarwal S; Gerdes J; Wilson PA; Davis ES; Awes AN; O'Brien E; Mavencamp T; Koch HP; Poulsen DJ; Rhoderick JF; Chamberlin AR; Kavanaugh MP; Bridges RJ
    Neuropharmacology; 2005 Nov; 49(6):850-61. PubMed ID: 16183084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters.
    Shimamoto K; Lebrun B; Yasuda-Kamatani Y; Sakaitani M; Shigeri Y; Yumoto N; Nakajima T
    Mol Pharmacol; 1998 Feb; 53(2):195-201. PubMed ID: 9463476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxic and neuroprotective effects of the glutamate transporter inhibitor DL-threo-beta-benzyloxyaspartate (DL-TBOA) during physiological and ischemia-like conditions.
    Bonde C; Sarup A; Schousboe A; Gegelashvili G; Zimmer J; Noraberg J
    Neurochem Int; 2003; 43(4-5):371-80. PubMed ID: 12742081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of the substrate inhibitor l-trans-pyrrolidine-2,4-dicarboxylate (PDC) and the non-substrate inhibitor DL-threo-beta-benzyloxyaspartate (DL-TBOA) of glutamate transporters on neuronal damage and extracellular amino acid levels in rat brain in vivo.
    Montiel T; Camacho A; Estrada-Sánchez AM; Massieu L
    Neuroscience; 2005; 133(3):667-78. PubMed ID: 15890455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.
    Lin X; Stenvang J; Rasmussen MH; Zhu S; Jensen NF; Tarpgaard LS; Yang G; Belling K; Andersen CL; Li J; Bolund L; Brünner N
    BMC Genomics; 2015 May; 16(1):404. PubMed ID: 25997618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,25-Dihydroxyvitamin D induces the glutamate transporter SLC1A1 and alters glutamate handling in non-transformed mammary cells.
    Beaudin S; Welsh J
    Mol Cell Endocrinol; 2016 Mar; 424():34-41. PubMed ID: 26774511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters.
    Shimamoto K; Otsubo Y; Shigeri Y; Yasuda-Kamatani Y; Satoh M; Kaneko S; Nakagawa T
    Mol Pharmacol; 2007 Jan; 71(1):294-302. PubMed ID: 17047096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
    Plasencia C; Abad A; Martinez-Balibrea E; Taron M
    Invest New Drugs; 2004 Nov; 22(4):399-409. PubMed ID: 15292710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transporter reversal as a mechanism of glutamate release from the ischemic rat cerebral cortex: studies with DL-threo-beta-benzyloxyaspartate.
    Phillis JW; Ren J; O'Regan MH
    Brain Res; 2000 Jun; 868(1):105-12. PubMed ID: 10841893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
    Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
    Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.
    Bommer UA; Vine KL; Puri P; Engel M; Belfiore L; Fildes K; Batterham M; Lochhead A; Aghmesheh M
    Cell Commun Signal; 2017 Feb; 15(1):9. PubMed ID: 28143584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
    Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
    Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
    Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
    Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
    Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells.
    Buß I; Hamacher A; Sarin N; Kassack MU; Kalayda GV
    Metallomics; 2018 Mar; 10(3):414-425. PubMed ID: 29417972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
    El Khoury F; Corcos L; Durand S; Simon B; Le Jossic-Corcos C
    Int J Oncol; 2016 Dec; 49(6):2558-2568. PubMed ID: 27748801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamate transporter dysfunction associated with nerve injury-induced pain in mice.
    Napier IA; Mohammadi SA; Christie MJ
    J Neurophysiol; 2012 Jan; 107(2):649-57. PubMed ID: 22072505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.